Accendra Health, Inc. ACH
0.71
(0.02)
(2.74%)
as of 25 Sep
- Market cap
- $59.2M
- P/E
- 0.0×
Follow ACH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.10 | 0.06 | 0.08 | 0.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.09) | (3.48) | 3.16 | (2.15) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.96 | 0.71 | 0.72 | 3.17 | |
EV/EBITDA |
8.95 | 7.52 | 8.20 | 7.89 | |
EV/Operating CF |
(14.16) | (16.61) | (19.48) | (24.79) | |
EV/FCF |
(12.11) | (12.52) | (8.81) | (8.81) | |
Quick Ratio |
0.19 | 0.37 | 0.40 | 0.10 | |
Current Ratio |
0.41 | 0.49 | 0.58 | 0.86 | |
Net Debt/EBITDA |
55.99 | 22.40 | (31.79) | 8.99 | |
Debt/Assets |
81.52% | 87.05% | 83.61% | 52.41% | |
Debt/Equity |
(3.12) | (4.53) | (4.45) | (4.92) | |
Asset Turnover |
0.85 | 0.75 | 0.78 | 0.17 | |
Operating CF/Net income |
0.29 | 7.74 | (1.21) | 1.15 | |
Capex/Depreciation |
(0.51) | 0.87 | (0.20) | (0.32) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
39.72% | 40.66% | 38.30% | 38.13% | |
Intangible Assets out of Total Assets |
0.62 | 0.55 | 0.56 | 0.35 | |
Share Based Compensation of Revenue |
0.65% | 0.49% | (0.63%) | 1.15% | |
Graham Net Nets |
(9.10) | (13.15) | (10.98) | (6.29) | |
Graham Number |
25.14 | 43.84 | 43.90 | 46.64 | |
Earnings Yield |
(114.33%) | (616.23%) | (510.36%) | (362.50%) | |
Free Cash Flow Yield |
(80.41%) | (88.94%) | (104.57%) | (75.05%) | |
Revenue per Share |
8.00 | 8.21 | 9.22 | 9.02 | |
Operating CF per Share |
(0.34) | (0.66) | 0.89 | (2.23) | |
Capex per Share |
(0.43) | 0.71 | 0.20 | (0.86) | |
Free Cash Flow per Share |
(0.77) | 0.05 | 1.09 | (3.09) | |
Cash per Share |
0.10 | 4.41 | 3.67 | 0.42 | |
Shareholders Equity per Share |
(7.18) | (6.08) | (5.99) | (5.56) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(7.18) | (6.08) | (5.99) | (5.56) | |
Free Cash Flow |
(59.35) | 3.85 | 83.50 | (238.90) | |
Working Capital |
(394.77) | (614.60) | (399.20) | (334.29) | |
Capital Expenditures |
(33.34) | 53.93 | 15.31 | (66.38) | |
Net Current Asset Value |
(2,386.90) | (2,292.25) | (2,364.87) | (2,334.06) | |
EV/EBIT |
87.01 | 78.27 | 72.22 | 0.00 | |
Capex to Sales |
0.05 | (0.09) | (0.02) | 0.10 | |
Net Profit Margin |
(14.52%) | (1.03%) | (7.94%) | (21.55%) | |
Price to Operating Income |
8.94 | 7.03 | 7.84 | 0.00 | |
| Other line items | |||||
Average Receivables |
158.23 | 341.94 | 157.09 | 432.20 | |
Average Payables |
354.92 | 877.78 | 361.75 | 838.87 | |
Average Inventory |
71.29 | 736.91 | 71.01 | 653.15 | |
Average Assets |
3,130.98 | 3,636.20 | 3,553.96 | 4,558.75 | |
Average Common Equity |
(415.97) | 53.11 | 62.69 | 222.54 |
Columns are period end dates